Our History

Crystec forms a strategic partnership with Intertek focused on advancing formulation science and accelerating development timelines for inhaled medicines, particularly dry powder inhaler (DPI) products.

Crystec establishes Inhalis Therapeutics SA, a Swiss joint venture with SignalRX Pharmaceuticals and ADYA Sagl to develop a novel inhaled treatment for Idiopathic Pulmonary Fibrosis.
Crystec establishes a strategic partnership in China with Dalian Jeol Ltd. focused on modernisation of Traditional Chinese Medicines.

Crystec establish a new R&D centre in Haimen, jiangsu Province, China. The facility is part of the Yangtze Delta Advanced Drug Development platform, which is dedicated to accelerating pharmaceutical product innovation.

Crystec secures prestigious Newton Fund Research and Innovation Bridges programme, in partnership with the Shanghai Institute of Material Medical, Imperial College London and the Royal Brompton Hospital. The project will develop new respiratory therapeutics for the Chinese market.

Crystec builds commercial-scale GMP mSAS facility in partnership with Juniper Pharmaceutical Services, now Catalent Pharma Solutions (Nottingham, UK).

Crystec appointed to lead the supercritical fluid workstream of the UK's Advanced Manufacturing Supply Chain Initiative (AMSCI) REMediES project (https://remediesproject.com/).

Allergan acquires MAP Pharmaceuticals for $958m, to gain full control of the DHE SCF migraine product.

Crystec secures InnovateUK SMART award progress its lead asset, and on-demand therapy for the treatment of urge incontinence, into animal studies.

Crystec builds its research to commercial scale-up plant in Tianjin. First Chinese development project secured focused on the modernisation of Traditional Chinese Medicine.

Crystec begins work on an in-house pipeline of repurposed therapeutic assets for a range of indications

Bradford (UK) and Tianjin (China) research centres opened. Crystec works with its first multinational client.

CrystecPharma (Crystec) is formed by Peter York, Paul Thorning and Qun Shao to relaunch SCF technology for the pharmaceutical industry. The platform is updated and development of the modified Supercritical Anti-Solvent (mSAS) technology begins. Previous employees from Nektar, who had been involved in the DHE product join Crystec, including Lyn Daintree (product design), George Townend (engineering), Dan Ledger (Process robustness and scale-up).

Nektar Therapeutics completes Exubera insulin deal with Pfizer using an unrelated technology platform. The company decides to focus its resources on diabetes therapy and closes its SCF business.

Nektar Therapeutics licenses its inhaled formulation of DHE to MAP Pharmaceuticals.

bpd acquired by Inhale Therapeutic Systems Inc. for US$200m. Inhale subsequently renamed as Nektar Therapeutics apply SCF technology to the development of an in-house portfolio of products, including an inhaled reformulation of dihydroergotamine (DHE) for the treatment of migraine.

Professor Peter York and colleagues at the University of bradford conduct the first research into the application of supercritical fluid (SCF) technology to the formulation of pharmaceutical products. A spin-out company is formed, Bradford Particle Design (bpd), to commercialise the technology. The company works with a number of major pharmaceutical companies.